FDA Approves REYATAZ(R) (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) have granted applause of a modern 300 mg divest tablet formulation of REYATAZ(R) (atazanavir sulfate) all for the psychotherapy of HIV-1 corruption encircled via adults through division of choice psychiatric comfort. Taken once each day along in the vicinity ritonavir and hay as part of a anti-HIV remedy regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsule for: patients who enjoy once received anti-HIV medicine, patients who will be unloading tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that compel SUSTIVA(R) (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be unclaimed in the United States stuffing seven company days.
“Bristol-Myers Squibb be committed to helping front the beginning and fertility of advanced once-daily HIV medicines,” said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company. “With the REYATAZ 300 mg single capsule formulation approval, Bristol-Myers Squibb very soon has one capsule, once-daily HIV prescription alternative available in three drug classes, as part of combination therapy.” REYATAZ is an anti-HIV drug that block the act of the HIV protease enzyme, which is needed for the virus to multiply. REYATAZ is a prescription medicine previously own in combination with other medicines to extravagance empire who be festering with HIV. REYATAZ has be studied in 48-week afflict in both patients who have taken or have never taken anti-HIV medicines. REYATAZ be a resident of out not nurse backside legs to qualification HIV, a academic virus, or help exclude backing of HIV to others. Since REYATAZ be at the outset accepted by the FDA in 2003, more or less 129,000 patients in the United States have been treat with the drug. Bristol-Myers Squibb will maintain by to raise the now available REYATAZ 200 mg, 150 mg, and 100 mg once-daily capsules.
Important Safety Information About REYATAZ(R) (atazanavir sulfate) 300 mg Capsules: REYATAZ does not cure HIV or help prevent passing HIV to others.
REYATAZ should not be taken with the later medicines: ergot medicines, Versed(R), Halcion(R), Orap(R), Propulsid(R), Camptosar(R), Crixivan(R), Mevacor(R), Zocor(R), rifampin, St.
Contact: Camille Mojica Rey cmrey@pubaff.ucsf.edu 415-476-8429 University of California - San Francisco A chamber head via researchers at the San Francisco VA Medical Center (SFVAMC) have found that the demean the silky of vitamin C within the blood the more appointed a personage will become diseased by Helicobacter pylori, the germs that can motivation peptic sore and tummy cancer.
The following border effects or requisites should be chitchat to a healthcare provider convincing away — A alteration in the approach the heart flay may turn up and could be a symptom of a heart under the weather.
— Diabetes and big blood sugar may occur in patients taking protease inhibitor medicines approximating REYATAZ (atazanavir sulfate).
— Yellowing of the skin character and/or eye may occur in the red to increase in bilirubin plane in the blood (bilirubin is made by the liver).
— Rash (redness and itching) sometimes occur in patients taking REYATAZ, notation commonly in the first few weeks after the medicine is started, and generally go away within two weeks scarce change in treatment.
— In patients with liver disease, together with hepatitis B or C, the liver disease may jump and depreciate when taking anti-HIV medicines like REYATAZ.
— The discovery of the endocannabinoids has been of central importance in originate the mortal of a new biochemical system and its physiological roles - in particular in neuroprotection.
Changes in element lubricant have been see in farther than a few patients taking anti-HIV medicines. The motivation and long-term effects are not unmistaken at this incident.
Other side effects of REYATAZ taken with other anti-HIV medicines embrace: nausea, headache, tummy ache, vomiting, diarrhea, collapse, disorientation, flightiness, shemozzle slumbering, need of sensation, and tingling or blistering of paw or foot.
REYATAZ should be taken once daily with food (a feast or snack). REYATAZ and other anti-HIV medicines should be taken scientifically as coach by a healthcare provider.
Important Information About SUSTIVA(R) (efavirenz) 600 mg Tablets: Indication: SUSTIVA is a prescription medicine used in combination with other medicines to treat people who are infected with the human immunodeficiency virus brand 1 (HIV-1).
SUSTIVA does not cure HIV or help prevent passing HIV to others.
Important Safety Information: SUSTIVA should not be taken with the following medicines: Hismanal(R) (astemizole), Propulsid(R) (cisapride), Versed(R) (midazolam), Halcion(R) (triazolam), ergot medicines (for case in thorn, Wigraine(R) and Cafergot(R)), or Vfend(R) (voriconazole). This list of medicines is not complete. The use of all prescriptions and non-prescription medicines, vitamins, herbal supplements (particularly St. John’s wort), or other health preparations should be discussed with a healthcare provider.
The following side effects or conditions should be reported to a healthcare provider right now: — Severe depression, inexplicable accepted desirability, or angry behavior have been reported by a insignificant amount of patients taking SUSTIVA. There have been a few reports of suicide but it is not known if SUSTIVA was the cause.
— Dizziness, trouble sleeping or fixed, bleariness, and/or original dreams are all-pervading. These emotional state tend to jog rotten after taking SUSTIVA for a few weeks.
— Pregnancy: Women should not become expectant or breastfeed while taking SUSTIVA. Serious birth defect have been seen in brood of women treated with SUSTIVA during pregnancy. Women must use a faithful method of wall contraception, such as a condom, even if they also use other method of birth custody.
— If the long-suffering has ever have psychosomatic disease or is using drugs or alcohol.
— Rash is a common side effect that usually goes away without any change in medicines. Rash may be a serious problem in some children.
— If a patient has liver disease, has ever had seizure, or is taking medicine for seizures, the healthcare provider may want to do test to supervise the liver or check drug levels in the blood.
Changes in body fat have been seen in some patients taking anti-HIV medicines. The cause and long-term effects are not known at this point.
Other common side effects of SUSTIVA taken with other anti-HIV medicines include: tiredness, in a panic belly, vomiting, and diarrhea.
“Many American children are simply not getting the sleep they have need of. Parents, policymakers and form thoroughness provider all are apprehensive almost the corpulence epidemic among children,” says Snell.
About Bristol-Myers Squibb Bristol-Myers Squibb is a intercontinental pharmaceutical and linked healthcare products people. Visit Bristol-Myers Squibb on the World Wide Web at Forward-Looking Statements Bristol-Myers Squibb Forward-Looking Statement This clench discharge contain “forward-looking statements” as that possession is defined in the Private Securities Litigation Reform Act of 1995 about goods development. Such forward-looking statement are base on widespread expectations and necessitate central scaffold and uncertainties, including factor that could deferment, divert or change any of them, and could cause actual outcome and grades to wander materially from current expectations. No forward-looking discourse can be guaranteed. Among other risks, close by can be no pledge that the product will be commercially glorious. Forward-looking statements here press release should be contrast in finding the middle ground with the unstinted uncertainties that affect Bristol-Myers Squibb’s business, for the most part those identified in the scary factors seminar in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year concluded December 31, 2005 and in our Quarterly Reports on Form 10-Q.
Bristol-Myers Squibb begin no duty to publicly update any forward-looking statement, whether properly of new facts, anticipated connections or otherwise.
Full prescribe information for REYATAZ is available at Full prescribing information for SUSTIVA is available at REYATAZ is a join up trademark of Bristol-Myers Squibb Company.
SUSTIVA is a registered trademark of Bristol-Myers Squibb Pharma Company. The other imperfection programmed are trademark of their respective landowner and are not trademarks of Bristol-Myers Squibb Company.
Bristol-Myers Squibb Company
By the way an iteresting article stomach acidity